Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
ACADIA Pharmaceuticals Community
NasdaqGS:ACAD Community
3
Narratives
written by author
0
Comments
on narratives written by author
83
Fair Values set
on narratives written by author
Community Investing Ideas
ACADIA Pharmaceuticals
Popular
Undervalued
Overvalued
ACADIA Pharmaceuticals
AN
AnalystLowTarget
Consensus Narrative from 19 Analysts
Medicare Negotiations And Patent Cliffs Will Stifle Revenues
Key Takeaways Reliance on a narrow product portfolio and vulnerability to pricing constraints threaten long-term revenue and margin stability. Regulatory, operational, and competitive pressures pose significant risks to growth, innovation, and future market share.
View narrative
US$18.37
FV
37.9% overvalued
intrinsic discount
8.19%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
about 9 hours ago
author updated this narrative
ACADIA Pharmaceuticals
AN
AnalystHighTarget
Consensus Narrative from 19 Analysts
Secular Trends And Pipeline Expansion Will Drive CNS Therapy Adoption
Key Takeaways Accelerated international growth and stronger than expected product adoption position ACADIA for substantial revenue and margin expansion across markets. Robust R&D pipeline, strategic financial management, and favorable demographic trends create opportunities for high-return pipeline growth and sustained earnings increases.
View narrative
US$40.00
FV
36.7% undervalued
intrinsic discount
16.37%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
2
users have followed this narrative
1 day ago
author updated this narrative
ACADIA Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 19 Analysts
Global Outreach And Pipeline Programs Will Expand CNS Markets
Key Takeaways Expanding product demand, strong pipeline progress, and strategic outreach are broadening the patient base and diversifying revenue streams, reducing reliance on single products. Favorable regulatory trends and industry consolidation are enabling faster market access and unlocking new partnership and growth opportunities.
View narrative
US$29.95
FV
15.4% undervalued
intrinsic discount
11.59%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
43
users have followed this narrative
2 days ago
author updated this narrative
Your Valuation for
ACAD
ACAD
ACADIA Pharmaceuticals
Your Fair Value
US$
Current Price
US$25.33
9.8% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-306m
2b
2015
2018
2021
2024
2025
2027
2030
Revenue US$1.7b
Earnings US$372.2m
Advanced
Set Fair Value